当前位置:首页 - 行情中心 - 蓝丰生化(002513) - 财务分析 - 资产负债表

蓝丰生化

(002513)

  

流通市值:18.82亿  总市值:24.45亿
流通股本:2.89亿   总股本:3.76亿

资产负债表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
流动资产:
  货币资金617,973,606.65895,394,896.331,114,276,042.31768,571,956.9
  结算备付金-0--
  拆出资金-0--
  交易性金融资产-0--
  衍生金融资产-0--
  应收票据及应收账款827,628,721.05804,233,375.16493,583,392.75545,494,891.11
  其中:应收票据134,152,821.35147,706,317.57139,080,553.52154,924,251.96
        应收账款693,475,899.7656,527,057.59354,502,839.23390,570,639.15
  应收款项融资3,077,420.594,082,596.783,642,302.42482,607.38
  预付款项222,512,889.08167,598,873.16179,263,070.12169,276,324.87
  应收保费-0--
  应收分保账款-0--
  应收分保合同准备金-0--
  其他应收款合计59,676,588.1962,698,021.55103,668,749.7695,667,904.65
  其中:应收利息-0--
        应收股利-0--
  买入返售金融资产-0--
  存货210,308,056.75297,072,948.51361,417,578.73277,705,022.52
  合同资产-0--
  一年内到期的非流动资产-0--
  其他流动资产66,564,286.2765,753,644.0743,336,408.6631,038,926.42
  流动资产合计2,007,741,568.582,296,834,355.562,299,187,544.751,888,237,633.85
非流动资产:
  长期应收款3,098,7583,098,758--
  长期股权投资12,434,935.5612,434,935.5613,205,956.7513,010,956.75
  其他权益工具投资-0--
  其他非流动金融资产-0--
  投资性房地产487,823.84492,025.49496,227.14500,428.79
  固定资产1,711,100,888.561,767,776,909.841,670,809,750.841,698,869,426.19
  在建工程4,643,697.892,789,431.08244,672,281.0325,482,596.29
  生产性生物资产-0--
  油气资产-0--
  使用权资产6,088,518.9114,726,585.3714,224,186.4310,170,088.12
  无形资产61,886,941.3762,507,670.0961,337,548.1663,129,026.85
  开发支出-0--
  商誉-0--
  长期待摊费用14,689,930.7315,341,099.648,738,089.35540,731.78
  递延所得税资产228,671,860.72224,665,634.79229,547,506.68224,233,376.67
  其他非流动资产9,534,945.476,187,601.83100,949,539.0183,213,741.39
  非流动资产合计2,052,638,300.982,180,020,651.692,343,981,085.392,119,150,372.83
  资产总计4,060,379,869.564,476,855,007.254,643,168,630.144,007,388,006.68
流动负债:
  短期借款86,045,393.38113,569,510.48220,585,297.89182,135,820.72
  向中央银行借款-0--
  吸收存款及同业存放-0--
  交易性金融负债00--
  应付票据及应付账款1,687,731,435.162,004,159,958.52,105,353,242.831,792,883,686.1
  其中:应付票据609,478,638.88918,129,544.651,073,136,240.72797,905,492.41
        应付账款1,078,252,796.281,086,030,413.851,032,217,002.11994,978,193.69
  预收款项5,116,126.855,116,126.85--
  合同负债89,772,976.9788,782,728.43110,246,807.2270,752,520.47
  卖出回购金融资产款-0--
  应付手续费及佣金-0--
  应付职工薪酬12,156,257.9114,683,069.5618,413,554.8818,076,789.8
  应交税费10,588,789.4210,564,106.557,906,925.484,400,524.61
  其他应付款合计812,625,102.88766,377,101.34875,392,679.29696,806,424.02
  其中:应付利息-0--
        应付股利-0--
  应付分保账款-0--
  代理买卖证券款-0--
  代理承销证券款-0--
  一年内到期的非流动负债129,030,069.76136,769,096.4992,621,551.1973,382,700.06
  其他流动负债156,975,050.4166,486,449.6159,923,629.03173,803,947.16
  流动负债合计2,990,041,202.733,306,508,147.83,590,443,687.813,012,242,412.94
非流动负债:
  长期借款361,757,099.5344,060,000389,330,000389,330,000
  优先股-0--
  永续债-0--
  租赁负债7,177,266.6112,209,508.2510,900,406.458,728,363.27
  长期应付款102,257,960.23129,217,661.14102,004,991.1414,429,550.02
  长期应付职工薪酬24,033,501.0324,899,176.3621,947,242.8523,516,594.28
  预计负债10,360,298.4784,068,960.7581,151,870.7280,431,693.38
  递延收益213,942,310.07217,874,634.2217,423,506.59221,154,957.77
  递延所得税负债3,007,961.313,007,961.313,181,690.293,542,121.5
  其他非流动负债-0--
  非流动负债合计722,536,397.22815,337,902.01825,939,708.04741,133,280.22
  负债合计3,712,577,599.954,121,846,049.814,416,383,395.853,753,375,693.16
所有者权益(或股东权益):
  实收资本(或股本)375,593,978375,593,978355,563,978375,280,278
  其他权益工具-0--
  优先股-0--
  永续债-0--
  资本公积2,349,934,602.422,339,200,253.892,134,986,826.622,140,748,353.89
  减:库存股80,739,06080,739,06027,859,86078,754,800
  其他综合收益979,914.53990,094.081,161,006.081,161,006.08
  专项储备2,941,293.952,645,401.952,676,020.72,857,968.38
  盈余公积49,021,098.5649,021,098.5649,021,098.5649,021,098.56
  一般风险准备-0--
  未分配利润-2,657,642,413.79-2,643,022,564.99-2,529,679,285.94-2,497,276,167.84
  归属于母公司股东权益合计40,089,413.6743,689,201.49-14,130,215.98-6,962,262.93
  少数股东权益307,712,855.94311,319,755.95240,915,450.27260,974,576.45
  股东权益合计347,802,269.61355,008,957.44226,785,234.29254,012,313.52
  负债和股东权益合计4,060,379,869.564,476,855,007.254,643,168,630.144,007,388,006.68
公告日期2026-04-302026-04-182025-10-252025-08-28
审计意见(境内)标准无保留意见
TOP↑